tetano
Editor, Senior Moderator
Ann Clin Microbiol Antimicrob
. 2022 Nov 19;21(1):51.
doi: 10.1186/s12941-022-00542-2.
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study
Nuttakant Nontawong[SUP] 1 [/SUP], Taweegrit Siripongboonsitti[SUP] 2 3 [/SUP], Kriangkrai Tawinprai[SUP] 4 [/SUP], Mana Boonpratoom[SUP] 5 [/SUP], Nawin Krailassiri[SUP] 5 [/SUP], Chayaporn Boonkhum[SUP] 1 [/SUP], Kamonwan Soonklang[SUP] 6 [/SUP], Yong Poovorawan[SUP] 7 [/SUP], Nithi Mahanonda[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) causes life-threatening pneumonia. Convalescent plasma therapy (CPT) is expected to be the effective COVID-19 treatment for passive immunity. The high neutralizing antibodies titer of CPT is needed to prove the benefit in early developed severe COVID-19.
Objective: This case-control study evaluated transfusion efficacy and adverse events with high-titer (≥ 1:320) COVID-19 convalescent plasma compared with standard care alone in severe COVID-19 pneumonia.
Results: Among 107 severe COVID-19 patients, 55 received CPT plus standard care, and 52 received standard care alone. All-cause mortality was 15.3% in the CPT group compared with 85.4% in the standard care group (p < 0.001). Univariate and multivariate analyses revealed reduced mortality with CPT (HR 0.14; 95% CI 0.07-0.31; p < 0.001 and HR 0.26; 95% CI 0.08-0.79; p = 0.018, respectively). CPT resulted in decreased use of mechanical ventilation, duration of supplemental oxygen, and high-flow oxygen requirement. Clinical and radiological outcomes improved.
Conclusions: Immediate high neutralizing antibody titer CPT is safe and reduces mortality in early developed severe COVID-19 patients. The benefit of CPT in the early course of illness is challenging and requires additional study. Trial registration Thai clinical trials registry (TCTR) no. 20220101003.
Keywords: COVID-19; Convalescent plasma; Mortality; Severe COVID-19.
. 2022 Nov 19;21(1):51.
doi: 10.1186/s12941-022-00542-2.
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study
Nuttakant Nontawong[SUP] 1 [/SUP], Taweegrit Siripongboonsitti[SUP] 2 3 [/SUP], Kriangkrai Tawinprai[SUP] 4 [/SUP], Mana Boonpratoom[SUP] 5 [/SUP], Nawin Krailassiri[SUP] 5 [/SUP], Chayaporn Boonkhum[SUP] 1 [/SUP], Kamonwan Soonklang[SUP] 6 [/SUP], Yong Poovorawan[SUP] 7 [/SUP], Nithi Mahanonda[SUP] 8 [/SUP]
Affiliations
- PMID: 36403020
- DOI: 10.1186/s12941-022-00542-2
Abstract
Background: Coronavirus disease 2019 (COVID-19) causes life-threatening pneumonia. Convalescent plasma therapy (CPT) is expected to be the effective COVID-19 treatment for passive immunity. The high neutralizing antibodies titer of CPT is needed to prove the benefit in early developed severe COVID-19.
Objective: This case-control study evaluated transfusion efficacy and adverse events with high-titer (≥ 1:320) COVID-19 convalescent plasma compared with standard care alone in severe COVID-19 pneumonia.
Results: Among 107 severe COVID-19 patients, 55 received CPT plus standard care, and 52 received standard care alone. All-cause mortality was 15.3% in the CPT group compared with 85.4% in the standard care group (p < 0.001). Univariate and multivariate analyses revealed reduced mortality with CPT (HR 0.14; 95% CI 0.07-0.31; p < 0.001 and HR 0.26; 95% CI 0.08-0.79; p = 0.018, respectively). CPT resulted in decreased use of mechanical ventilation, duration of supplemental oxygen, and high-flow oxygen requirement. Clinical and radiological outcomes improved.
Conclusions: Immediate high neutralizing antibody titer CPT is safe and reduces mortality in early developed severe COVID-19 patients. The benefit of CPT in the early course of illness is challenging and requires additional study. Trial registration Thai clinical trials registry (TCTR) no. 20220101003.
Keywords: COVID-19; Convalescent plasma; Mortality; Severe COVID-19.